Lilly lifts its financial outlook by $10 billion as demand for GLP-1 treatments continues to exceed expectations and sales momentum remains stronger than previously projected

Lilly lifts its financial outlook by $10 billion as demand for GLP-1 treatments continues to exceed expectations and sales momentum remains stronger than previously projected